Detection of ovarian cancer by 198au‐labeled human monoclonal antibody

Tandra R. Chaudhuri, Kurt R. Zinn, J. Steven Morris, Gregory A. McDonald, Alfred S. Llorens, Tuhin K. Chaudhuri

Research output: Contribution to journalArticle

Abstract

Background. There is no reliable method for the early diagnosis of ovarian cancer. Radiolabeled monoclonal antibodies have potential to assist in early diagnosis, but they are limited by problems that include antibody specificity, stability, and immunoreactivity, as well as patient reactions to the antibodies used. Methods. Methods were developed to 198Au‐label a human monoclonal antibody (TC5 antibody), developed against an ovarian cancer cell surface antigen. Antigen binding sites on the TC5 antibody were protected with sepharose 4B affinity chromatography before 198Au‐labeling. The 198Au‐labeled TC5 antibody was evaluated with biopsy specimens in a blind study. The immunoreactivity of radiolabeled TC5 antibody also was evaluated in slotblot experiments with extracts of the biopsy specimens. Results. The 198Au‐labeled TC5 antibody had high binding reaction to all biopsy specimens (six of six) pathologically diagnosed as ovarian cancer (serous and endometrioid adenocarcinoma). The radiolabeled TC5 antibody did not bind to any normal (non‐neoplastic) specimens (zero in ten), with one exception. One “normal” ovary specimen had high binding of radiolabeled TC5 antibody, and metastatic ovarian cancer was diagnosed 4 months later. The TC5 antibody labeled with 198Au, without protecting antigen‐binding sites, did not bind to any biopsy specimens. Conclusions. The affinity‐labeling method was necessary to protect antigen‐binding sites and preserve the immunoreactivity of the TC5 antibody. The 198Au‐labeling method may be an ideal technique to evaluate monoclonal antibodies in vitro. The TC5 antibody had high sensitivity and specificity for detecting ovarian cancer. Cancer 1994; 73:878–83.

Original languageEnglish (US)
Pages (from-to)878-883
Number of pages6
JournalCancer
Volume73
Issue number3 S
DOIs
StatePublished - 1994

Fingerprint

Ovarian Neoplasms
Monoclonal Antibodies
Antibodies
Biopsy
Endometrioid Carcinoma
Antibody Specificity
Surface Antigens
Affinity Chromatography
Early Detection of Cancer
Sepharose
Early Diagnosis
Ovary
Binding Sites
Antigens
Sensitivity and Specificity

Keywords

  • Au
  • Au‐198
  • human monoclonal antibody, ovarian cancer
  • radioimmunodiagnosis
  • radiolabeling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chaudhuri, T. R., Zinn, K. R., Steven Morris, J., McDonald, G. A., Llorens, A. S., & Chaudhuri, T. K. (1994). Detection of ovarian cancer by 198au‐labeled human monoclonal antibody. Cancer, 73(3 S), 878-883. https://doi.org/10.1002/1097-0142(19940201)73:3+<878::AID-CNCR2820731319>3.0.CO;2-U

Detection of ovarian cancer by 198au‐labeled human monoclonal antibody. / Chaudhuri, Tandra R.; Zinn, Kurt R.; Steven Morris, J.; McDonald, Gregory A.; Llorens, Alfred S.; Chaudhuri, Tuhin K.

In: Cancer, Vol. 73, No. 3 S, 1994, p. 878-883.

Research output: Contribution to journalArticle

Chaudhuri, TR, Zinn, KR, Steven Morris, J, McDonald, GA, Llorens, AS & Chaudhuri, TK 1994, 'Detection of ovarian cancer by 198au‐labeled human monoclonal antibody', Cancer, vol. 73, no. 3 S, pp. 878-883. https://doi.org/10.1002/1097-0142(19940201)73:3+<878::AID-CNCR2820731319>3.0.CO;2-U
Chaudhuri, Tandra R. ; Zinn, Kurt R. ; Steven Morris, J. ; McDonald, Gregory A. ; Llorens, Alfred S. ; Chaudhuri, Tuhin K. / Detection of ovarian cancer by 198au‐labeled human monoclonal antibody. In: Cancer. 1994 ; Vol. 73, No. 3 S. pp. 878-883.
@article{4b682177d7b644738ebf2fbffaa35013,
title = "Detection of ovarian cancer by 198au‐labeled human monoclonal antibody",
abstract = "Background. There is no reliable method for the early diagnosis of ovarian cancer. Radiolabeled monoclonal antibodies have potential to assist in early diagnosis, but they are limited by problems that include antibody specificity, stability, and immunoreactivity, as well as patient reactions to the antibodies used. Methods. Methods were developed to 198Au‐label a human monoclonal antibody (TC5 antibody), developed against an ovarian cancer cell surface antigen. Antigen binding sites on the TC5 antibody were protected with sepharose 4B affinity chromatography before 198Au‐labeling. The 198Au‐labeled TC5 antibody was evaluated with biopsy specimens in a blind study. The immunoreactivity of radiolabeled TC5 antibody also was evaluated in slotblot experiments with extracts of the biopsy specimens. Results. The 198Au‐labeled TC5 antibody had high binding reaction to all biopsy specimens (six of six) pathologically diagnosed as ovarian cancer (serous and endometrioid adenocarcinoma). The radiolabeled TC5 antibody did not bind to any normal (non‐neoplastic) specimens (zero in ten), with one exception. One “normal” ovary specimen had high binding of radiolabeled TC5 antibody, and metastatic ovarian cancer was diagnosed 4 months later. The TC5 antibody labeled with 198Au, without protecting antigen‐binding sites, did not bind to any biopsy specimens. Conclusions. The affinity‐labeling method was necessary to protect antigen‐binding sites and preserve the immunoreactivity of the TC5 antibody. The 198Au‐labeling method may be an ideal technique to evaluate monoclonal antibodies in vitro. The TC5 antibody had high sensitivity and specificity for detecting ovarian cancer. Cancer 1994; 73:878–83.",
keywords = "Au, Au‐198, human monoclonal antibody, ovarian cancer, radioimmunodiagnosis, radiolabeling",
author = "Chaudhuri, {Tandra R.} and Zinn, {Kurt R.} and {Steven Morris}, J. and McDonald, {Gregory A.} and Llorens, {Alfred S.} and Chaudhuri, {Tuhin K.}",
year = "1994",
doi = "10.1002/1097-0142(19940201)73:3+<878::AID-CNCR2820731319>3.0.CO;2-U",
language = "English (US)",
volume = "73",
pages = "878--883",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3 S",

}

TY - JOUR

T1 - Detection of ovarian cancer by 198au‐labeled human monoclonal antibody

AU - Chaudhuri, Tandra R.

AU - Zinn, Kurt R.

AU - Steven Morris, J.

AU - McDonald, Gregory A.

AU - Llorens, Alfred S.

AU - Chaudhuri, Tuhin K.

PY - 1994

Y1 - 1994

N2 - Background. There is no reliable method for the early diagnosis of ovarian cancer. Radiolabeled monoclonal antibodies have potential to assist in early diagnosis, but they are limited by problems that include antibody specificity, stability, and immunoreactivity, as well as patient reactions to the antibodies used. Methods. Methods were developed to 198Au‐label a human monoclonal antibody (TC5 antibody), developed against an ovarian cancer cell surface antigen. Antigen binding sites on the TC5 antibody were protected with sepharose 4B affinity chromatography before 198Au‐labeling. The 198Au‐labeled TC5 antibody was evaluated with biopsy specimens in a blind study. The immunoreactivity of radiolabeled TC5 antibody also was evaluated in slotblot experiments with extracts of the biopsy specimens. Results. The 198Au‐labeled TC5 antibody had high binding reaction to all biopsy specimens (six of six) pathologically diagnosed as ovarian cancer (serous and endometrioid adenocarcinoma). The radiolabeled TC5 antibody did not bind to any normal (non‐neoplastic) specimens (zero in ten), with one exception. One “normal” ovary specimen had high binding of radiolabeled TC5 antibody, and metastatic ovarian cancer was diagnosed 4 months later. The TC5 antibody labeled with 198Au, without protecting antigen‐binding sites, did not bind to any biopsy specimens. Conclusions. The affinity‐labeling method was necessary to protect antigen‐binding sites and preserve the immunoreactivity of the TC5 antibody. The 198Au‐labeling method may be an ideal technique to evaluate monoclonal antibodies in vitro. The TC5 antibody had high sensitivity and specificity for detecting ovarian cancer. Cancer 1994; 73:878–83.

AB - Background. There is no reliable method for the early diagnosis of ovarian cancer. Radiolabeled monoclonal antibodies have potential to assist in early diagnosis, but they are limited by problems that include antibody specificity, stability, and immunoreactivity, as well as patient reactions to the antibodies used. Methods. Methods were developed to 198Au‐label a human monoclonal antibody (TC5 antibody), developed against an ovarian cancer cell surface antigen. Antigen binding sites on the TC5 antibody were protected with sepharose 4B affinity chromatography before 198Au‐labeling. The 198Au‐labeled TC5 antibody was evaluated with biopsy specimens in a blind study. The immunoreactivity of radiolabeled TC5 antibody also was evaluated in slotblot experiments with extracts of the biopsy specimens. Results. The 198Au‐labeled TC5 antibody had high binding reaction to all biopsy specimens (six of six) pathologically diagnosed as ovarian cancer (serous and endometrioid adenocarcinoma). The radiolabeled TC5 antibody did not bind to any normal (non‐neoplastic) specimens (zero in ten), with one exception. One “normal” ovary specimen had high binding of radiolabeled TC5 antibody, and metastatic ovarian cancer was diagnosed 4 months later. The TC5 antibody labeled with 198Au, without protecting antigen‐binding sites, did not bind to any biopsy specimens. Conclusions. The affinity‐labeling method was necessary to protect antigen‐binding sites and preserve the immunoreactivity of the TC5 antibody. The 198Au‐labeling method may be an ideal technique to evaluate monoclonal antibodies in vitro. The TC5 antibody had high sensitivity and specificity for detecting ovarian cancer. Cancer 1994; 73:878–83.

KW - Au

KW - Au‐198

KW - human monoclonal antibody, ovarian cancer

KW - radioimmunodiagnosis

KW - radiolabeling

UR - http://www.scopus.com/inward/record.url?scp=0028049184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028049184&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940201)73:3+<878::AID-CNCR2820731319>3.0.CO;2-U

DO - 10.1002/1097-0142(19940201)73:3+<878::AID-CNCR2820731319>3.0.CO;2-U

M3 - Article

C2 - 8306273

AN - SCOPUS:0028049184

VL - 73

SP - 878

EP - 883

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3 S

ER -